Clear Search

Showing 2 result for “Diehl A”.

January 2023

トファシチニブ開発プログラムにおける関節リウマチ, 潰 瘍性大腸炎, 乾癬性関節炎患者のインフルエンザ

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00507-z

This post-hoc analysis of 31 clinical trials in ulcerative colitis, rheumatoid arthritis and psoriatic arthritis concludes that combined influenza adverse event incidence rates were highest in ulcerative colitis, while in each indication they were generally similar across tofacitinib, placebo, and comparator groups.


トファシチニブとメトトレキサート併用で治療され、メトト レキサートを中止した関節リウマチ患者の疾患活動性

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00511-3

This post hoc analysis of data from the ORAL Shift study, concludes that DAS28-4(ESR), CDAI remission and SDAI remission are the metrics most likely to reflect actual disease activity, in the context of tofacitinib in a randomised withdrawal of MTX.